Sign in:
 Email
 Password  save:
  
 Company Reports 
 
 
Membership is free, please Sign Up.
  
My Recent Searches
  Help
  
   
 
 
Get Insiders for : 
Biomarin Pharmaceutical Inc (BMRN)  
$88.63 1.44 (1.6%) as of 4:30 Fri 4/19


Download
   
Exchange: Nasdaq National Market
Security Type: Common
Shares Out: 188,370,000
Market Cap: 16.70(B)
Last Volume: 1,778,607 Avg Vol: 1,398,026
52 Week Range: $76.22 - $99
Level I Sector: Health Care
Level II Sector: Drugs
Level III Sector: Drug Manufacturers - Other

Member Indexes:
    NASDAQ BIOTECHNOLOGY     NASDAQ COMPOSITE
    NASDAQ NNM COMPOSITE

Rankings:
     
Insider 3 Months    :   -
Insider 6 Months    :   -
Insider 3/6 Months :   -
Guru Rank Number :  811
Guru Rank Value     : 0.9
Guru Occurances    : 1

 

            6 Months   1 Year   2 Year  
 
Company Profile   BioMarin Pharmaceutical is a biotechnology company that develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Co.'s commercial products are Aldurazyme (laronidase) for Mucopolysaccharidosis I; Brineura (cerliponase alfa) for the treatment of late infantile neuronal ceroid lipofuscinosis type 2; Kuvan (sapropterin dihydrochloride) for the treatment of phenylketonuria; Naglazyme (galsulfase) the treatment of Mucopolysaccharidosis VI ; Palynziq (pegvaliase-pqpz) for adult patients with phenylketonuria; and Vimizim (elosulfase alpha) for the treatment of Mucopolysaccharidosis IV Type A.

 
 
Summary  (Direct Transactions Only) 3 Months 6 Months 12 Months 24 Months
Total Shares Bought 0 0 0 3,625
Total Buy Value $0 $0 $0 $314,469
Total People Bought 0 0 0 1
Total Buy Transactions 0 0 0 1
Total Shares Sold 159,588 275,693 319,053 656,089
Total Sell Value $13,270,852 $23,760,160 $27,661,182 $61,420,002
Total People Sold 5 6 7 7
Total Sell Transactions 10 21 27 56
End Date 2024-03-07 2023-12-05 2023-06-06 2022-06-06

   
Records found: 2582
  Page 10 of 104  
Filer's Name Relation Title Off-Dir-10% Tran. Date Form Action Price Mkt Value D/I Shares Holdings
Rank

  
3m +/-  
Form
   Bienaime Jean Jacques Chief Executive Officer   •       •      –    2022-04-18 4 OE $37.46 $749,200 D/D 20,000 354,983     -
   Bienaime Jean Jacques Chief Executive Officer   •       •      –    2022-04-14 4 AS $83.66 $836,600 D/D (10,000) 334,983     -
   Bienaime Jean Jacques Chief Executive Officer   •       •      –    2022-04-14 4 OE $37.46 $374,600 D/D 10,000 344,983     -
   Lawlis V Bryan Director   –       •      –    2022-04-14 4 AS $83.66 $355,555 D/D (4,250) 23,970     -
   Lawlis V Bryan Director   –       •      –    2022-04-14 4 OE $37.46 $159,205 D/D 4,250 28,220     -
   Ajer Jeffrey Robert EVP, Chief Commercial Officer   •       –      –    2022-04-13 4 AS $82.47 $97,315 D/D (1,180) 55,077     -
   Ajer Jeffrey Robert EVP, Chief Commercial Officer   •       –      –    2022-03-30 4 AS $79.56 $109,872 D/D (1,381) 56,257     -
   Ajer Jeffrey Robert EVP, Chief Commercial Officer   •       –      –    2022-03-29 4 AS $79.43 $128,518 D/D (1,618) 57,638     -
   Ajer Jeffrey Robert EVP, Chief Commercial Officer   •       –      –    2022-03-23 4 AS $81.78 $501,230 D/D (6,129) 59,256     -
   Ajer Jeffrey Robert EVP, Chief Commercial Officer   •       –      –    2022-03-22 4 AS $81.00 $167,913 D/D (2,073) 65,385     -
   Davis George Eric EVP, General Counsel   •       –      –    2022-03-21 4 AS $81.29 $498,226 D/D (6,129) 63,329     -
   Fuchs Henry J President, Worldwide R&D   •       –      –    2022-03-16 4 D $80.72 $182,346 D/D (2,259) 143,753     -
   Bienaime Jean Jacques Chief Executive Officer   •       •      –    2022-03-16 4 D $80.72 $448,803 D/D (5,560) 334,983     -
   Ajer Jeffrey Robert EVP, Chief Commercial Officer   •       –      –    2022-03-16 4 D $80.72 $103,887 D/D (1,287) 67,458     -
   Mueller Brian EVP, Chief Financial Officer   •       –      –    2022-03-16 4 D $80.72 $46,979 D/D (582) 38,299     -
   Davis George Eric EVP, General Counsel   •       –      –    2022-03-16 4 D $80.72 $101,061 D/D (1,252) 69,458     -
   Fuchs Henry J President, Worldwide R&D   •       –      –    2022-03-15 4 D $78.27 $947,145 D/D (12,101) 146,012     -
   Fuchs Henry J President, Worldwide R&D   •       –      –    2022-03-15 4 A $0.00 $0 D/D 38,790 158,113     -
   Bienaime Jean Jacques Chief Executive Officer   •       •      –    2022-03-15 4 D $78.27 $2,998,211 D/D (38,306) 340,543     -
   Bienaime Jean Jacques Chief Executive Officer   •       •      –    2022-03-15 4 A $0.00 $0 D/D 40,280 378,849     -
   Ajer Jeffrey Robert EVP, Chief Commercial Officer   •       –      –    2022-03-15 4 D $78.27 $658,877 D/D (8,418) 68,745     -
   Ajer Jeffrey Robert EVP, Chief Commercial Officer   •       –      –    2022-03-15 4 A $0.00 $0 D/D 11,940 77,163     -
   Mueller Brian EVP, Chief Financial Officer   •       –      –    2022-03-15 4 D $78.27 $146,208 D/D (1,868) 38,881     -
   Mueller Brian EVP, Chief Financial Officer   •       –      –    2022-03-15 4 A $0.00 $0 D/D 11,040 40,749     -
   Davis George Eric EVP, General Counsel   •       –      –    2022-03-15 4 D $78.27 $648,858 D/D (8,290) 70,710     -
  2582 Records found
  Previous  10  11  12  13  14  15  16  17  18  19  Next   
  Page 10 of 104
  Transaction Code Key: Ownership Code Key
  B - Buy AB - Automatic Buy D - Direct Ownership
  S - Sell AS - Automatic Sell I - Indirect Ownership
  OE - Options Exercised A - Acquired
  IO - Initital Ownership D - Disposed
 
 
    Copyright © 2024 j3sg.com | Disclaimer & Terms of use          Products & Service  About Us  Contact Us